Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Davide Cusumano, Alessandro Scaggion, Yolande Lievens, Enrico Clementel, Sarah Nuyens, Filippo Alongi, Sergi Benavente, Pètra Braam, Piet Dirix, Hossein Hemmatazad, Paul Jeene, Daniela Greto, Sara Ramella, Jasna But-Hadzic, Juan Salinas, Marta Scorsetti, Igor Sirak, Karin Stellamans, Joachim Widder, Piet Ost, Matthias Guckenberger
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Recent developments in radiotherapy
10.1056/nejmra1608986 · 2017
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium
10.1016/s1470-2045(22)00752-5 · 2023
What will radiation oncology look like in 2050? A look at a changing professional landscape in Europe and beyond
10.1002/1878-0261.12731 · 2020
An international modified Delphi study to prioritise levels of evidence and outcomes to appraise radiotherapy innovation in the ESTRO value-based radiation oncology framework
10.1016/s1470-2045(25)00732-6 · 2026
Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium
10.1016/s1470-2045(26)00075-6 · 2026
Assessing the gold standard--lessons from the history of RCTs
10.1056/nejmms1604593 · 2016
Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective
10.1016/s1470-2045(18)30917-3 · 2019
Real-world evidence - what is it and what can it tell us?
10.1056/nejmsb1609216 · 2016
Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: an interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study
10.1016/j.radonc.2024.110235 · 2024
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European organisation for research and treatment of Cancer consensus recommendation
10.1016/s1470-2045(19)30718-1 · 2020
Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: real-world data from the E2-RADIatE OligoCare cohort
2024
Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: an interim analysis of the E2-RADIatE OligoCare cohort
10.1016/j.radonc.2024.110466 · 2024
Cost evaluation to optimise radiation therapy implementation in different income settings: a time-driven activity-based analysis
10.1016/j.radonc.2017.08.021 · 2017
Unresolved referenced work
2025
Unresolved referenced work
Kept as external metadata until matched
European Groundshot-addressing Europe’s cancer research challenges: a lancet oncology commission
10.1016/s1470-2045(22)00540-x · 2023
Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments
10.1016/s1470-2045(23)00182-1 · 2023
Costs of drug development and Research and Development intensity in the US, 2000-2018
10.1001/jamanetworkopen.2024.15445 · 2024
Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey
10.1016/j.radonc.2014.08.034 · 2014
No additional external references are available.